Increased neuroactive steroid concentrations in women with bipolar disorder or major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 26, Issue 4, 2006, Pages 379-384

  Hardoy, Maria Carolina ^a   Serra, Mariangela ^a,b   Carta, Mauro Giovanni ^a   Contu, Paolo ^a   Pisu, Maria Giuseppina ^b   Biggio, Giovanni ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 3ALPHA,21 DIHYDROXY 5ALPHA PREGNAN 20 ONE; HYDROCORTISONE; PROGESTERONE; STEROID;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; EATING DISORDER; FEMALE; HUMAN; LUTEAL PHASE; MAJOR DEPRESSION; MENSTRUAL CYCLE; MOOD DISORDER; NEUROPSYCHIATRY; OBSESSIVE COMPULSIVE DISORDER; PANIC; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; STEROID BLOOD LEVEL; WELLBEING;

ADULT; ANTI-INFLAMMATORY AGENTS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; DESOXYCORTICOSTERONE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; HYDROCORTISONE; PREGNANOLONE; PREMENOPAUSE; PREMENSTRUAL SYNDROME; PROGESTERONE; RADIOIMMUNOASSAY; STEROIDS;

EID: 33746891173     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000229483.52955.ec     Document Type: Article

References (47)

1. Majewska MD, Harrison NL, Schwartz RD, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986;232:1004-1007.
2. Bitran D, Shiekh M, Mcleod M. Anxiolytic effect of progesterone is mediated by the neuroactive steroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol. 1995;7:171-177.
3. Biggio G, Follesa P, Sanna E, et al. GABAA-receptor plasticity during long-term exposure to and withdrawal from progesterone. Int Rev Neurobiol. 2001;46:207-241.
4. Biggio G, Dazzi L, Biggio F, et al. Molecular mechanisms of tolerance to and withdrawal of GABA(A) receptor modulators. Eur Neuropsychopharmacol. 2002;13:411-423.
5. Mellon SH, Griffin LD, Compagnone NA. Biosynthesis and action of neuroactive steroids. Brain Res Rev. 2001;37:3-12.
6. Reddy DS, Rogawski MA. Stress-induced deoxycorticosterone-derived neuroactive steroids modulates GABAA receptor function and seizure susceptibility. J Neurosci. 2002;42:3795-3805.
7. Backstrom T, Sanders D, Leask R, et al. Mood, sexuality, hormones and the menstrual cycle: hormone levels and their relationship to the premenstrual syndrome. Psych Med. 1983;45:503-507.
8. Schmidt PJ, Purdy RH, Moore PH Jr, et al. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab. 1994;79:1256-1260.
9. Wang M, Seippel L, Purdy RH, et al. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. J Clin Endocrinol Metab. 1996;81:1076-1082.
10. Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol. 1997;190:709-714.
11. Bicikova M, Dibbelt L, Hill M, et al. Allopregnanolone in women with premenstrual syndrome. Horm Metab Res. 1998;30:227-230.
12. Strohle A, Romeo E, Hermann B, et al. Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry. 1999;45:274-277.
13. Strohle A, Romeo E, di Michele F, et al. GABAA receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am J Psychiatry. 2002;159:145-147.
14. Strohle A, Romeo E, di Michele F, et al. Induced panic attacks shift γ-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry. 2003;60:161-168.
15. Vanover KE, Rosenzweig-Lipson S, Hawkinson JE, et al. Characterization of the anxiolytic properties of a novel neuroactive steroid, Co 2-6749 (GMA-839; WAY-141839; 3α-21-dihydroxy-3β-trifluoromethyl-19-nor-5β- pregnan-20-one), a selective modulator of γ-aminobutyric acidA receptors. J Pharmacol Exp Ther. 2000;295:37-345.
16. Girdler SS, Straneva PA, Light KC, et al. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry. 2001;49:788-797.
17. Sundstrom Poromaa I, Smith SS, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Women Ment Health. 2003;6:23-41.
18. Reddy DS. Pharmacology of endogenous neuroactive steroids. Crit Rev Neurobiol. 2003;15:197-234.
19. Reddy DS, Kim HY, Rogawski MA. Neuroactive steroid withdrawal model of perimenstrual catamenial epilepsy. Epilepsia. 2001;42:328-336.
20. Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia. 2001;42:337-344.
21. Monteleone P, Fabrazzo P, Serra M, et al. Long-term treatment with clozapine does not affect morning circulating levels of allopregnanolone and THDOC in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol. 2004;24:437-440.
22. Romeo E, Ströhle A, Spalletta G, et al. Effect of antidepressant treatment on neuroactive steroids in major depression. Am J Psych. 1998;155:910-913.
23. Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A. 1998;95:3239-3244.
24. Rasgon N, Serra M, Biggio G, et al. Neuroactive steroid-serotoninergic interaction: responses to an intravenous L-tryptophan challenge in woman with premenstrual dysphoric disorder. Eur J Endocrinol. 2001;145:25-33.
25. Monteleone P, Luisi S, Tonetti A, et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol. 2000;142:269-273.
26. Brambilla F, Biggio G, Pisu MG, et al. Neurosteroid secretion in panic disorder. Psychiatry Res. 2003;118:107-116.
27. A receptor function. Trends Pharmacol Sci. 1995;16:295-303.
28. A receptor-complex. Neurosci Lett. 1992;135:273-275.
29. Serra M, Littera M, Pisu MG, et al. Steroidogenesis in rat brain induced by short- and long-term administration carbamazepine. Neuropharmacology. 2000;39:2448-2456.
30. Miller MN, Miller BE. Premenstrual exacerbations of mood disorders. Psychopharmacol Bull. 2001;35:135-149.
31. Arnold LM. Gender differences in bipolar disorder. Psychiatr Clin North Am. 2003;26:595-620.
32. Cassano GB, Pini S, Saettoni M, et al. Multiple anxiety disorder comorbidity in patients with mood spectrum disorders with psychotic features. Am J Psychiatry. 1999a;156:474-476.
33. Frank E, Cyranowski JM, Rucci P, et al. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen Psychiatry. 2002;59:905-911.
34. Cassano GB, Dell'Osso L, Frank E, et al. The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. J Affect Disord. 1999b;54:319-328.
35. Cassano GB, Frank E, Miniati M, et al. Conceptual underpinnings and empirical support for the mood spectrum. Psychiatr Clin North Am. 2000;25:699-712.
36. Cassano GB, Pini S. A spectrum model for mood disorders: a useful approach in clinical psychiatry in search of an assessment methodology. Epidemiol Psichiatr Soc. 2002;9:156-162.
37. Cassano GB, Rucci P, Frank E, et al. The mood spectrum in unipolar and bipolar disorder: arguments for a unitary approach. Am J Psychiatry. 2004;161:1264-1269.
38. Purdy RH, Morrow AL, Blinn JR, et al. Synthesis, metabolism, and pharmacological activity of 3α-hydroxy steroids which potentiate GABA receptor-mediated chloride ion uptake in rat cerebral cortical synaptoneurosomes. J Med Chem. 1990;33:1572-1581.
39. Barbaccia ML, Roscetti G, Trabucchi M, et al. Time dependent changes in rat brain neuroactive steroid concentrations and GABAA receptor function after acute stress. Neuroendocrinol. 1996;63:166-172.
40. George MS, Guidotti A, Rubinow D, et al. CSF neuroactive steroids in affective disorders: pregnenolone, progesterone, and DBI. Biol Psychiatry. 1994;35:775-780.
41. Barbaccia ML, Affricano D, Purdy RH, et al. Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacology. 2001;25:489-497.
42. Marx CE, Van doren MJ, Duncan GE, et al. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology. 2003;28:1-13.
43. Uzunov DP, Cooper TB, Costa E, et al. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci U S A. 1996;93:12599-12604.
44. Serra M, Pisu MG, Muggironi M, et al. Opposite effects of short- versus long-term administration of fluoxetine on the concentrations of neuroactive steroids in rat plasma and brain. Psychopharmacology. 2001;158:48-54.
45. Pisu MG, Serra M. Neurosteroids and neuroactive drugs in mental disorders. Life Sci. 2004;74:3181-3197.
46. Genazzani AR, Petraglia F, Bernardi F, et al. Circulating levels of allopregnanolone in humans: gender, age and endocrine influences. J Clin Endocrinol Metab. 1998;83:2099-2103.
47. Brambilla F, Biggio G, Pisu MG, et al. Plasma concentrations of anxiolytic neurosteroids in men with normal anxiety scores: a correlation analysis. Neuropsychobiology. 2004;50:6-9.